 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
23 News |  |
- AlphaMedix (ORM-2110) / RadioMedix, Orano, Sanofi
Targeted Alpha Therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors () - Nov 1, 2024 - Abstract #NANETS2024NANETS_121;
- || AlphaMedix (ORM-2110) / RadioMedix, Orano
Enrollment closed: ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Na (clinicaltrials.gov) - May 27, 2024
P2, N=69, Active, not recruiting, Sponsor: Radiomedix, Inc.
Recruiting --> Active, not recruiting
- AlphaMedix (ORM-2110) / RadioMedix, Orano
Safety, tolerability and efficacy of 212 Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study. (E451) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3953;
P2
Research Funding: No funding sources reported. In PRRT-na
- ||| AlphaMedix (ORM-2110) / RadioMedix, Orano
Enrollment change, Trial completion date, Trial primary completion date: ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Na (clinicaltrials.gov) - Oct 23, 2023
P2, N=68, Recruiting, Sponsor: Radiomedix, Inc.
In PRRT-na N=34 --> 68 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Dec 2022 --> Oct 2026
- |||| AlphaMedix (ORM-2110) / RadioMedix, Orano
Clinical: Fascinating presentations on the management of PRRT refractory patients: Definition & role of repeat PRRT by @AmanChauhanMD, 212Pb-DOTAMTATE alpha PRRT Dr Ebrahim Delpassand, and dosimetry & maintenance regimes by Dr Jean-Matthieu Beauregard. Lots of engagement! @NANETS1 (Twitter) - Oct 28, 2022
- AlphaMedix (ORM-2110) / RadioMedix, Orano
Early data on 212Pb-DOTAMTATE (JW Marriott Washington, D.C.) - Oct 23, 2022 - Abstract #NANETS2022NANETS_63;
- || AlphaMedix (ORM-2110) / RadioMedix, Orano
Clinical, P1 data, Journal: Targeted Alpha-Emitter Therapy With Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial. (Pubmed Central) - Oct 13, 2022
Targeted alpha therapy with Pb-DOTAMTATE has been shown to be a well-tolerated and highly effective treatment in patients with metastatic NETs. With an ORR of 80%, further development of Pb-DOTAMTATE is warranted as it represents a significant improvement over the current standard of care and has the potential to be a breakthrough alternative for the treatment of metastatic NETs.
- AlphaMedix (ORM-2110) / RadioMedix, Orano
Targeted alpha-emitter therapy with 212Pb-DOTAMTATE in neuroendocrine tumor subjects who progressed following prior 177Lu/90Y-PRRT. (Available On Demand; 114) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1965;
P1
This is the first clinical trial of 212Pb-targeted alpha-emitter therapy in subjects with NETs who progressed following prior PRRT. The use of 212Pb-DOTAMTATE in the recurrent setting is highly effective with manageable toxicity and warrants further investigation.
- || AlphaMedix (ORM-2110) / RadioMedix, Orano
Enrollment open: ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Na (clinicaltrials.gov) - Jan 10, 2022
P2, N=34, Recruiting, Sponsor: Radiomedix, Inc.
The use of 212Pb-DOTAMTATE in the recurrent setting is highly effective with manageable toxicity and warrants further investigation. Not yet recruiting --> Recruiting
- ||| AlphaMedix (ORM-2110) / RadioMedix, Orano
Targeted Alpha-Emitter Therapy is so powerful ! Pb212 is an excellent alternative to Ac-225 congrats for this first-in-human US study of 212Pb-DOTAMTATE @delpassand @JournalofNucMed @CzerninJohannes https://t.co/RTFioOGE5O (Twitter) - Jan 7, 2022
- || AlphaMedix (ORM-2110) / RadioMedix, Orano
New P2 trial: ALPHAMEDIX02: Targeted Alpha-emitter Therapy of PRRT Na (clinicaltrials.gov) - Dec 10, 2021
P2, N=34, Not yet recruiting, Sponsor: Radiomedix, Inc.
- || AlphaMedix (ORM-2110) / RadioMedix, Orano
Enrollment open, Trial completion date, Trial primary completion date: ALPHAMEDIX01: Phase 1 Study of AlphaMedix (clinicaltrials.gov) - Aug 24, 2021
P1, N=33, Recruiting, Sponsor: Radiomedix, Inc.
Not yet recruiting --> Recruiting Completed --> Recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
- || AlphaMedix (ORM-2110) / RadioMedix, Orano
Trial completion, Enrollment change, Trial completion date: ALPHAMEDIX01: Phase 1 Study of AlphaMedix (clinicaltrials.gov) - Jul 12, 2021
P1, N=33, Completed, Sponsor: Radiomedix, Inc.
Completed --> Recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022 Recruiting --> Completed | N=50 --> 33 | Trial completion date: Nov 2021 --> Jul 2021
- AlphaMedix (212Pb-labeled peptide) / RadioMedix, Orano
[VIRTUAL] Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1529;
P1
This F-I-H clinical study of AlphaMedix shows that PRRT with 212Pb is feasible, well tolerated, and provides substantial reduction in tumor burden to patients with unresectable, metastatic SSTR-expressing NETs . Dramatic improvement in tumor burden and a positive impact on quality of life were seen in all of the PRRT naïve subjects who AlphaMedix at the highest dose tested.
- | AlphaMedix (ORM-2110) / RadioMedix, Orano
Trial primary completion date: ALPHAMEDIX01: Phase 1 Study of AlphaMedix (clinicaltrials.gov) - Apr 26, 2021
P1, N=50, Recruiting, Sponsor: Radiomedix, Inc.
Dramatic improvement in tumor burden and a positive impact on quality of life were seen in all of the PRRT naïve subjects who AlphaMedix at the highest dose tested. Trial primary completion date: Jul 2020 --> Jun 2021
- AlphaMedix (212Pb-labeled peptide) / RadioMedix, Areva
[VIRTUAL] Oral Abstract Presenter - 212Pb-AlphaMedixTM Targeted Alpha Therapy (TAT): A Potential Breakthrough in Treatment of Metastatic SSTR Expressing NET (VIRTUAL POSTER HALL) - Oct 9, 2020 - Abstract #NANETS2020NANETS_177;
- AlphaMedix (212Pb-labeled peptide) / RadioMedix, Areva
[VIRTUAL] 212Pb-AlphaMedixTM Targeted Alpha Therapy (TAT): A potential breakthrough in treatment of metastatic SSTR expressing NET () - Oct 9, 2020 - Abstract #NANETS2020NANETS_106;
- |||| AlphaMedix (212Pb-labeled peptide) / RadioMedix, Areva
Clinical, P1 data, P2 data: Impressive work by @delpassand @alphamedix in this Phase 1 Targeted Alpha Therapy (TAT) study in NET patients. Great news--now moved to phase 2 including those previously treated w PRRT. Encouraging to the NET patient community! @NANETS1 @NANETSgoesvirtual @LACNETS (Twitter) - Oct 3, 2020
- |||| AlphaMedix (212Pb-labeled peptide) / RadioMedix, Areva
Clinical, P1 data, P2 data: Impressive work by @delpassand @alphamedix in this Phase 1 Targeted Alpha Therapy (TAT) study in NET patients. Great news--now moved to phase 2 including those previously treated w PRRT. Encouraging to the NET patient community! @NANETS1 @NANETSgoesvirtual @LACNETS (Twitter) - Oct 3, 2020
- |||| AlphaMedix (212Pb-labeled peptide) / RadioMedix, Areva
Clinical, P1 data: Exciting presentation by @delpassand about the phase I dose escalation results with 212-Pb-DOTAMTATE @alphamedix in patients with NETs. More to come! #NANETSgoesVirtual @NANETS1 #NANETS20 (Twitter) - Oct 3, 2020
- AlphaMedix (212Pb-labeled peptide) / RadioMedix, Areva
[VIRTUAL] First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of neuroendocrine tumors (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_159;
In addition, AlphaMedixTM was extremely well tolerated with only mild adverse events, most of which were attributable to the AA solution used for renal protection. This FIH study of AlphaMedixTM illustrates that PRRT with 212Pb is feasible, well-tolerated, and provides substantial reduction in tumor burden to patients with unresectable, metastatic SSTR expressing NETs
- || AlphaMedix (ORM-2110) / RadioMedix, Orano
Enrollment open: ALPHAMEDIX01: Phase 1 Study of AlphaMedix (clinicaltrials.gov) - Jan 7, 2020
P1, N=50, Recruiting, Sponsor: Radiomedix, Inc.
This FIH study of AlphaMedixTM illustrates that PRRT with 212Pb is feasible, well-tolerated, and provides substantial reduction in tumor burden to patients with unresectable, metastatic SSTR expressing NETs Active, not recruiting --> Recruiting
- | AlphaMedix (ORM-2110) / RadioMedix, Orano
Enrollment closed: ALPHAMEDIX01: Phase 1 Study of AlphaMedix (clinicaltrials.gov) - Aug 19, 2019
P1, N=50, Active, not recruiting, Sponsor: Radiomedix, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting